Literature DB >> 15356131

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity.

Riccardo Gavioli1, Eleonora Gallerani, Cinzia Fortini, Marina Fabris, Arianna Bottoni, Alessandro Canella, Angela Bonaccorsi, Mauro Marastoni, Fabiola Micheletti, Aurelio Cafaro, Paola Rimessi, Antonella Caputo, Barbara Ensoli.   

Abstract

Tat, the trans activation protein of HIV, is produced early upon infection to promote and expand HIV replication and transmission. However, Tat appears to also have effects on target cells, which may affect Ag recognition both during infection and after vaccination. In particular, Tat targets dendritic cells and induces their maturation and Ag-presenting functions, increasing Th1 T cell responses. We show in this work that Tat modifies the catalytic subunit composition of immunoproteasomes in B and T cells either expressing Tat or treated with exogenous biological active Tat protein. In particular, Tat up-regulates latent membrane protein 7 and multicatalytic endopeptidase complex like-1 subunits and down-modulates the latent membrane protein 2 subunit. These changes correlate with the increase of all three major proteolytic activities of the proteasome and result in a more efficient generation and presentation of subdominant MHC-I-binding CTL epitopes of heterologous Ags. Thus, Tat modifies the Ag processing and modulates the generation of CTL epitopes. This may have an impact on both the control of virally infected cells during HIV-1 infection and the use of Tat for vaccination strategies. Copyright 2004 The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356131     DOI: 10.4049/jimmunol.173.6.3838

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoire.

Authors:  Nicholas J Steers; Jeffrey R Currier; Gustavo H Kijak; Robert C di Targiani; Ashima Saxena; Mary A Marovich; Jerome H Kim; Nelson L Michael; Carl R Alving; Mangala Rao
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

Review 2.  Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.

Authors:  Flavia Ferrantelli; Stefano Buttò; Aurelio Cafaro; Britta Wahren; Barbara Ensoli
Journal:  Springer Semin Immunopathol       Date:  2006-09-16

3.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

4.  Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation.

Authors:  Jadwiga Turchan-Cholewo; Filomena O Dimayuga; Sunita Gupta; Jeffrey N Keller; Pamela E Knapp; Kurt F Hauser; Annadora J Bruce-Keller
Journal:  J Neurochem       Date:  2008-11-19       Impact factor: 5.372

5.  HIV-1 Tat regulates cyclin B1 by promoting both expression and degradation.

Authors:  Shi-Meng Zhang; Yi Sun; Rong Fan; Qin-Zhi Xu; Xiao-Dan Liu; Xiangming Zhang; Ya Wang; Ping-Kun Zhou
Journal:  FASEB J       Date:  2009-10-13       Impact factor: 5.191

6.  Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.

Authors:  Federica Destro; Fabio Sforza; Mariaconcetta Sicurella; Diego Marescotti; Eleonora Gallerani; Anna Baldisserotto; Mauro Marastoni; Riccardo Gavioli
Journal:  Immunology       Date:  2011-02-22       Impact factor: 7.397

Review 7.  Harnessing proteasome dynamics and allostery in drug design.

Authors:  Maria Gaczynska; Pawel A Osmulski
Journal:  Antioxid Redox Signal       Date:  2014-02-21       Impact factor: 8.401

8.  Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes.

Authors:  Rebecca Voltan; Arianna Castaldello; Egidio Brocca-Cofano; Giuseppe Altavilla; Antonella Caputo; Michele Laus; Katia Sparnacci; Barbara Ensoli; Silvia Spaccasassi; Marco Ballestri; Luisa Tondelli
Journal:  Pharm Res       Date:  2007-05-03       Impact factor: 4.200

9.  Patterns of HIV-1 protein interaction identify perturbed host-cellular subsystems.

Authors:  Jamie I MacPherson; Jonathan E Dickerson; John W Pinney; David L Robertson
Journal:  PLoS Comput Biol       Date:  2010-07-29       Impact factor: 4.475

10.  Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.

Authors:  Barbara Ensoli; Stefania Bellino; Antonella Tripiciano; Olimpia Longo; Vittorio Francavilla; Simone Marcotullio; Aurelio Cafaro; Orietta Picconi; Giovanni Paniccia; Arianna Scoglio; Angela Arancio; Cristina Ariola; Maria J Ruiz Alvarez; Massimo Campagna; Donato Scaramuzzi; Cristina Iori; Roberto Esposito; Cristina Mussini; Florio Ghinelli; Laura Sighinolfi; Guido Palamara; Alessandra Latini; Gioacchino Angarano; Nicoletta Ladisa; Fabrizio Soscia; Vito S Mercurio; Adriano Lazzarin; Giuseppe Tambussi; Raffaele Visintini; Francesco Mazzotta; Massimo Di Pietro; Massimo Galli; Stefano Rusconi; Giampiero Carosi; Carlo Torti; Giovanni Di Perri; Stefano Bonora; Fabrizio Ensoli; Enrico Garaci
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.